A clinical-stage oncology opportunity is developing a first-in-class small-molecule approach designed to modulate oncogenic protein expression by targeting structured regulatory elements within mRNA. The asset is being advanced for advanced and refractory solid tumours, supported by preclinical efficacy, tumour penetration, target engagement, safety data, and CTA-enabled clinical development. Strategic partners and investors interested in novel RNA-targeted oncology modalities, tumour resistance, and translational control may find this opportunity relevant.
